Generate Biomedicines (NASDAQ:GENB) Sees Large Volume Increase – Here’s What Happened

Shares of Generate Biomedicines Inc (NASDAQ:GENB) saw unusually-strong trading volume on Thursday . Approximately 355,208 shares traded hands during trading, a decline of 34% from the previous session’s volume of 541,570 shares.The stock last traded at $14.8650 and had previously closed at $12.91.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on GENB shares. The Goldman Sachs Group started coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective for the company. Piper Sandler began coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price target on the stock. Wall Street Zen cut shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Cantor Fitzgerald began coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating on the stock. Finally, HC Wainwright boosted their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Generate Biomedicines presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

Generate Biomedicines Stock Performance

The stock has a fifty day moving average price of $13.19.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.